The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nakayama, T.
Right arrow Articles by Yoshie, O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nakayama, T.
Right arrow Articles by Yoshie, O.
The Journal of Immunology, 2004, 173: 2078-2083.
Copyright © 2004 by The American Association of Immunologists

Liver-Expressed Chemokine/CC Chemokine Ligand 16 Attracts Eosinophils by Interacting with Histamine H4 Receptor1

Takashi Nakayama*, Yoshiko Kato{dagger}, Kunio Hieshima*, Daisuke Nagakubo*, Yuichi Kunori{ddagger}, Takao Fujisawa{dagger} and Osamu Yoshie2,*,§

* Department of Microbiology, Kinki University School of Medicine, Osaka, Japan; {dagger} Department of Pediatrics and Allergy, National Mie Hospital, Mie, Japan; {ddagger} Teijin Institute for Biomedical Research, Hino, Tokyo, Japan; and § Solution Oriented Research for Science and Technology of the Japanese Science and Technology Corporation, Tokyo, Japan


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Liver-expressed chemokine (LEC)/CCL16 is a human CC chemokine that is constitutively expressed by the liver parenchymal cells and present in the normal plasma at high concentrations. Previous studies have shown that CCL16 is a low-affinity ligand for CCR1, CCR2, CCR5, and CCR8 and attracts monocytes and T cells. Recently, a novel histamine receptor termed type 4 (H4) has been identified and shown to be selectively expressed by eosinophils and mast cells. In this study, we demonstrated that CCL16 induced pertussis toxin-sensitive calcium mobilization and chemotaxis in murine L1.2 cells expressing H4 but not those expressing histamine receptor type 1 (H1) or type 2 (H2). CCL16 bound to H4 with a Kd of 17 nM. By RT-PCR, human and mouse eosinophils express H4 but not H3. Accordingly, CCL16 induced efficient migratory responses in human and mouse eosinophils. Furthermore, the responses of human and mouse eosinophils to CCL16 were effectively suppressed by thioperamide, an antagonist for H3 and H4. Intravenous injection of CCL16 into mice induced a rapid mobilization of eosinophils from bone marrow to peripheral blood, which was also suppressed by thioperamide. Collectively, CCL16 is a novel functional ligand for H4 and may have a role in trafficking of eosinophils.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Chemokines play important roles in innate and acquired immunity by inducing directed migration of various types of leukocytes through interactions with a group of seven-transmembrane G protein-coupled receptors (GPCRs)3 (1). Liver-expressed chemokine (LEC)/CCL16 (2), also known as novel CC chemokine 4 (2), human CC chemokine 4 (3), lymphocyte and monocyte chemoattractant (4), and liver-specific CC chemokine 1 (5), is selectively expressed in the liver and present in the normal plasma at high concentrations (6). CCL16 was shown to be induced in monocytes by IL-10 (3) and chemotactic for monocytes and lymphocytes (3, 4). In addition, this chemokine was shown to have a potent myelosuppressive activity comparable to that of MIP-1{alpha}/CCL3 (4) and to induce tumor rejection (7). Previously, we have shown that CCL16 is a low-affinity functional ligand for CCR1, CCR2, and CCR5 (6). Separately, Howard et al. (8) reported that CCL16 induced chemotaxis and cell adhesion to matrix proteins of human monocytes via CCR1 and CCR8. However, its physiological role still remains mostly unknown.

Histamine receptor type 4 (H4) is the most recently identified subtype of histamine receptors (9, 10). H4 is selectively expressed by cells such as eosinophils and mast cells and mediates histamine-induced chemotaxis and calcium mobilization in these types of cells (11, 12). Chemoattractant receptors including those for chemokines often interact with quite diverse molecules. For example, CCR6, the receptor for CCL20 (1), is also a receptor for {beta}-defensins (13). HIV-1 Tat protein attracts monocytes via CCR2 and CCR3 (14). Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, the autoantigens in myositis, attract T cells, IL-2-activated monocytes, and immature dendritic cells via CCR5 and CCR3, respectively (15). Formyl peptide receptor-like 1, the low-affinity receptor for the bacterial chemotactic peptide fMLF, is also a receptor for lipoxin A4 and acute phase protein serum amyloid A (16, 17). Given such versatility in the chemoattractant receptors in terms of ligand-specificity, we tested a large panel of human chemokines on histamine receptors H1, H2, and H4 (18). In this study, we report that CCL16 is a functional ligand for H4 and induces an efficient migration of human and mouse eosinophils via H4.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Materials

All recombinant human chemokines were purchased from R&D Systems (Minneapolis, MN). Histamine and thioperamide were purchased from Sigma-Aldrich (St. Louis, MO). Pertussis toxin (PTX) was purchased from Invitrogen (Carlsbad, CA). A murine L1.2 pre-B cell line was kindly provided by E. Butcher (Stanford University School of Medicine, Stanford, CA).

Stable expression of histamine receptors

The coding regions of human histamine receptors H1, H2, and H4 were amplified from a cDNA library generated from PHA-stimulated PBMC by PCR. The cDNAs were cloned into a retroviral vector pMX-IRES/EGFP (19) and recombinant retroviruses were obtained. L1.2 cells were infected with the recombinant viruses and stable transfectants expressing green fluorescence were selected by FACS.

Calcium mobilization assay

Cells were suspended at 106 cells/ml in HBSS containing 1 mg/ml BSA and 10 mM HEPES (pH 7.4), and loaded with 3 µM Fura 2-AM fluorescence dye (Molecular Probes, Eugene, OR). After washing, cells were placed in F2000 fluorescence spectrophotometer (Hitachi, Tokyo, Japan) and stimulated with recombinant human chemokines or histamine. Emission fluorescence at 510 nm was measured upon excitation at 340 and 380 nm to obtain the fluorescence intensity ratio (R340/380).

Chemotaxis assay

This was conducted using Transwell plates with 5-µm pore polycarbonate membrane filters (Costar, Acton, MA) as described previously (20). Migrated cells were quantitated using PicoGreen dsDNA quantitation reagent (Molecular Probes) (20).

Binding assay

Recombinant human CCL16 was radiolabeled to a specific activity of 1.2 x 107 cpm/µg by using 125I-labeled Bolton and Hunter reagent (Amersham Biosciences, Piscataway, NJ). For binding experiments, 1 x 106 cells were incubated with 125I-labeled CCL16 without or with increasing concentrations of competitors in 200 µl of RPMI 1640 containing 20 mM HEPES (pH 7.4) and 0.1% BSA. After incubation at 15°C for 1 h, cells were washed five times and counted in a gamma counter. The binding data were analyzed using GraphPad PRISM (GraphPad Software, San Diego, CA).

RT-PCR analysis

This was conducted as described previously (20). In brief, total RNA was prepared from cells using TRIzol reagent (Life Technologies, Gaithersburg, MD) and further purified using RNeasy (Qiagen, Hilden, Germany). Total RNA samples prepared from human and mouse tissues were also purchased from BD Biosciences (Mountain View, CA). Total RNA (1 µg) was reverse transcribed using oligo(dT)18 primer and SuperScript II reverse transcriptase (Life Technologies). Resulting first-strand DNA (equivalent to 20 ng of total RNA) and original total RNA (20 ng) were amplified in a final volume of 20 µl containing 10 pmol of each primer and 1 U of Ex-Taq polymerase (Takara Shuzo, Kyoto, Japan). The amplification conditions were denaturation at 94°C for 30 s (5 min for the first cycle), annealing at 60°C for 30 s, and extension at 72°C for 30 s (5 min for the last cycle) for 36 cycles for human and mouse H3 and H4 and 27 cycles for human and mouse GAPDH. The amplification products (10 µl each) were separated by electrophoresis on 2% agarose and stained with ethidium bromide. The primers used were: +5'-CCACTGTATGTACCCTACGTGCTG-3' and –5'-ATGCTGAGGTTAAAGAAGGTGACG-3' for human H3; +5'-AGCTATGACCGATTCCTGTCAGTC-3' and –5'-CCTCTGGATGTTCAGGTAGATGCT-3' for mouse H3; +5'-ATGCCAGATACTAATAGC-3' and –5'-TTAAGAAGATACTGACCG-3' for human H4; +5'-TGTGGTGGACAGAAACCTTAGACA-3' and –5'-AAGAATCTGAAGCCAGAATCATCG-3' for mouse H4; and +5'-GCCAAGGTCATCCATGACAACTTTGG-3' (+) and –5'-GCCTGCTTCACCACCTTCTTGATGTC-3' (–) for human and mouse GAPDH.

Preparation of human and mouse eosinophils

Human eosinophils were prepared from peripheral blood of healthy volunteers with no history of allergy as previously described (11). In brief, buffy coat cells were obtained from venous blood by dextran T500 sedimentation. Eosinophils were isolated by density centrifugation on Percoll (1.088 g/ml; Pharmacia Biotech, Uppsala, Sweden). The eosinophils were further purified by negative selection using anti-CD16-bound micromagnetic beads and a magnetic-activated cell sorter column (Miltenyi Biotec, Bergisch Gladbach, Germany). After negative selection, the purity of eosinophils was consistently >99%, and their viability was consistently >95%. Mouse eosinophils were separated from spleens of mice that had been injected i.m. with DNA of an IL-5 expression plasmid as previously described (21). In brief, female BALB/c mice, 8 wk old, were purchased from CLEA (Tokyo, Japan) and kept in specific pathogen-free conditions for at least 1 wk before experiments. Mice were injected into the bilateral soleus muscles with 50 µl of 0.25% bupivacaine (Sigma-Aldrich) using a disposable insulin syringe. At 3 and 10 days, mice were injected with 75 µg of pCAGGS-IL-5 plasmid DNA in 50 µl of PBS into bupivacaine-injected sites. After 2–3 wk, splenic eosinophils were purified from mice that had >50% eosinophils in the blood. Spleen cells were layered onto a discontinuous Percoll density gradient consisting of 1.06, 1.07, and 1.09 g/ml and were centrifuged at 250 x g for 20 min. Eosinophils were layered between 1.07 and 1.09 g/ml. Eosinophils were further purified by two times negative selection using anti-CD90 (Thy1.2), anti-CD45R (B220), and anti-CD8{alpha} (Ly-2)-bound micromagnetic beads and IMagnet (BD Biosciences). After negative selections, the purity of eosinophils was consistently >90%, and their viability was consistently >95%.

Eosinophil mobilization in mice

Female BALB/c mice, 6 wk old, were purchased from CLEA and kept in specific pathogen-free conditions for at least 1 wk before experiments. Mice were injected i.v. with 100 µl of PBS without or with 0.5 nmol of CCL16. At various time points, mice were given anesthesia by inhalation of diethyl ether and peripheral blood was collected. After blood collection, mice were sacrificed by cervical dislocation and femurs were obtained. The ends of femurs were removed and bone marrow cells were recovered by flushing with 1 ml of PBS. Smears were stained with May-Grünwald and Giemsa solutions. Differential cell counts were performed for at least 500 cells/slide. All animal experiments were performed in accordance with the guideline of the Center of Animal Experiments, Kinki University School of Medicine.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
CCL16 induces calcium mobilization via H4

Histamine receptors H1, H2, and H4 are variably expressed by hemopoietic cells, while H3 is selectively expressed by neurons in the CNS (10, 11, 12, 18). To examine whether any chemokines act as an agonist for the histamine receptors, we performed calcium mobilization assays using murine L1.2 pre-B cells stably expressing H1, H2, or H4 (L1.2-H1, L1.2-H2, and L1.2-H4, respectively). Among 32 recombinant human chemokines tested at 100 nM (CC chemokines: CCL1, 2, 3, 4, 5, 7, 8, 11, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 24, 25, 26, 27, and 28; CXC chemokines: CXCL4, 8, 9, 10, 12, 13, and 16; XCL1; CX3CL1), CCL16 was found to induce vigorous calcium mobilization in L1.2-H4. Fig. 1A shows that, while histamine induced calcium mobilization via H1, H2, and H4, CCL16 dose-dependently induced calcium mobilization via H4 but not via H1 or H2. Furthermore, H4-mediated calcium mobilization induced by CCL16 was completely suppressed by PTX, supporting that H4 couples with the G{alpha}i class of G proteins (9, 10). Fig. 1B shows that CCL16 dose-dependently desensitized histamine-induced calcium mobilization via H4. Conversely, histamine desensitized CCL16-induced calcium mobilization via H4. Furthermore, thioperamide, an antagonist for H3 and H4 (10, 22), completely suppressed CCL16- and histamine-induced calcium mobilization via H4. Collectively, CCL16 is a novel agonist for H4.



View larger version (17K):
[in this window]
[in a new window]
  		FIGURE 1. Induction of calcium mobilization in H4-expressing L1.2 cells by CCL16. A, H4-specific calcium mobilization by CCL16. L1.2 cells stably expressing H1 (L1.2-H1), H2 (L1.2-H2), or H4 (L1.2-H4) were loaded with Fura 2-AM. Cells (5 x 105/assay) were stimulated with CCL16 or histamine at indicated concentrations. Intracellular calcium mobilization was measured on a fluorescence spectrophotometer. Pretreatment of L1.2-H4 cells with PTX at 500 ng/ml was performed at 37°C for 30 min. Representative results from three separate experiments are shown. B, Mutual desensitization of CCL16 and histamine in calcium mobilization via H4. L1.2-H4 cells were loaded with Fura 2-AM and stimulated with CCL16 or histamine as indicated. Intracellular calcium mobilization was measured on a fluorescence spectrophotometer. Thioperamide was used at 50 µM. Representative results from three separate experiments are shown.

 
CCL16 induces chemotactic responses via H4

We next examined chemotactic responses of L1.2-H1, L1.2-H2, and L1.2-H4 to CCL16. As shown in Fig. 2A, both CCL16 and histamine induced vigorous cell migration in L1.2-H4 with a typical bell-shaped dose-response curve. In contrast, neither CCL16 nor histamine induced any significant migration in L1.2-H1 or L1.2-H2. Thus, these histamine receptors are not coupled with the G{alpha}i class of G proteins in L1.2 cells. As shown in Fig. 2B, thioperamide, an antagonist for H3 and H4 (10, 22), dose-dependently suppressed migratory responses of L1.2-H4 to 100 nM CCL16 with an IC50 of 50 µM. As shown in Fig. 2C, CCL16 and histamine were additive in inducing migration of L1.2-H4 cells. As shown in Fig. 2D, a checkerboard-type analysis confirmed that CCL16 induced mostly chemotaxis, not chemokinesis, in L1.2-H4. As shown in Fig. 2E, PTX, the inhibitor of the G{alpha}i class of G proteins, suppressed CCL16-induced migratory responses of L1.2-H4.



View larger version (26K):
[in this window]
[in a new window]
  		FIGURE 2. Induction of chemotaxis in H4-expressing L1.2 cells by CCL16. A, Dose-response experiments. Chemotactic responses of L1.2 cells stably expressing H1 (L1.2-H1), H2 (L1.2-H2), and H4 (L1.2-H4) to indicated concentrations of histamine and CCL16 were examined. B, Inhibition of CCL16-induced migration of L1.2-H4 cells by thioperamide. Chemotactic responses of L1.2-H4 cells to CCL16 at 100 nM were determined in the presence of indicated concentrations of thioperamide. C, Additive effects of histamine and CCL16. Chemotactic responses of L1.2-H4 cells to indicated concentrations of CCL16 without ({square}) or with 10 nM of histamine ({blacksquare}) were determined. D, A checkerboard-type analysis. In chemotactic assays using L1.2-H4 cells, CCL16 was added to upper and/or lower wells at 100 nM as indicated. E, Inhibition by PTX. L1.2-H4 cells were pretreated at 37°C for 30 min without or with PTX at 500 ng/ml and examined for chemotactic responses to CCL16 at 100 nM. All assays were done in duplicate and numbers of cells migrated to lower wells were expressed by percent input cells. Results are shown as mean ± SEM from three separate experiments.

 
Specific binding of CCL16 to H4

We next examined binding of CCL16 to H4. As shown in Fig. 3A, 125I-labeled CCL16 specifically bound to L1.2-H4. Scatchard analysis revealed a single class of binding sites with a Kd of 17 nM and 41,000 sites/cell (Fig. 3B). Furthermore, binding of 125I-labeled CCL16 at 10 nM was completely inhibited by unlabeled CCL16, histamine, and thioperamide with an IC50 of 8.8, 4.1, and 57 nM, respectively (Fig. 3C).



View larger version (19K):
[in this window]
[in a new window]
  		FIGURE 3. Specific binding of CCL16 to H4. A, Saturable binding of 125I-labeled CCL16 to L1.2-H4. Nonspecific bindings were determined in the presence of 100-fold molar excess unlabeled CCL16 and subtracted from total bindings. Representative results from three separate experiments are shown. B, Scatchard analysis of the binding data in A. The calculated Kd is 17 nM. C, Displacement experiments. L1.2-H4 cells were incubated with 125I-labeled CCL16 at 10 nM in the presence of various concentrations of unlabeled CCL16 (•), histamine ({circ}), or thioperamide ({diamondsuit}). Representative results from three separate experiments are shown. The calculated IC50 is 8.8 nM for CCL16, 4.1 nM for histamine, and 57 nM for thioperamide.

 
Eosinophil responses to CCL16

H4 is selectively expressed by eosinophils and mediates eosinophil migration to histamine (10, 11). By RT-PCR, we confirmed that human and mouse eosinophils expressed H4 but not H3 (Fig. 4A). We, therefore, examined induction of eosinophil migratory responses by CCL16. As shown in Fig. 4B (left), CCL16 dose-dependently induced a highly efficient migration of human eosinophils. In fact, many more eosinophils migrated to CCL16 at 100 or 1000 nM than to eotaxin/CCL11 at its optimal concentration of 10 nM. CCL16 also induced less efficient but still vigorous migration in mouse eosinophils (Fig. 4B, right). Furthermore, thioperamide, an antagonist for H3 and H4 (10, 22), dose-dependently suppressed migratory responses of human and mouse eosinophils to CCL16 (Fig. 4C). Fig. 4D further shows induction of calcium mobilization in mouse eosinophils by CCL16 and histamine as well as their mutual desensitization. Again, thioperamide completely suppressed CCL16-induced calcium mobilization in mouse eosinophils.



View larger version (24K):
[in this window]
[in a new window]
  		FIGURE 4. Induction of migration and calcium mobilization in human and mouse eosinophils by CCL16 via H4. A, RT-PCR analysis for expression of H3 and H4 in human and mouse eosinophils. Human eosinophils were obtained from four donors. cDNA samples from brain and bone marrow served as positive controls for H3 and H4, respectively. Representative results from two separate experiments are shown. B, Chemotactic responses of human and mouse eosinophils to CCL16. Chemotactic responses of human (left) and mouse (right) eosinophils to CCL16 at indicated concentrations (•) and to eotaxin/CCL11 at 10 nM ({circ}) were determined. Each point represents mean ± SEM from four separate experiments. C, Effect of thioperamide on eosinophil migration to CCL16. Chemotactic responses of human and mouse eosinophils to CCL16 at 100 nM were determined in the presence of indicated concentrations of thioperamide. Each point represents mean ± SEM from three separate experiments. D, Induction of calcium mobilization in mouse eosinophils by CCL16. Mouse eosinophils preloaded with Fura 2-AM were stimulated with CCL16 or histamine at indicated concentrations (5 x 106 cells/assay). Intracellular calcium mobilization was measured on a fluorescence spectrophotometer. Thioperamide was used at 50 µM. Representative results from three separate experiments are shown.

 
Eosinophil mobilization from mouse bone marrow by CCL16

Expression of H4 was consistently seen in the human, rat, mouse, and guinea pig bone marrow (Fig. 4A) (10, 22). Since CCL16 is selectively expressed in the liver and present in the normal plasma at relatively high concentrations (6), it may be involved in mobilization of eosinophils from the bone marrow. To test this possibility, we injected PBS without or with CCL16 into mice via the tail vein. As shown in Fig. 5A (left), eosinophil counts but not those of lymphocytes or neutrophils in the peripheral blood were rapidly increased in CCL16-injected mice with a peak at 60 min. Reciprocally, eosinophil counts but not those of lymphocytes or neutrophils in the bone marrow were rapidly decreased in CCL16-injected mice (Fig. 5A, right). Furthermore, thioperamide effectively suppressed CCL16-induced increases in blood eosinophils and decreases in bone marrow eosinophils, without affecting the numbers of lymphocytes or neutrophils (Fig. 5B). Collectively, CCL16 indeed induced a selective mobilization of eosinophils from the bone marrow via H4.



View larger version (32K):
[in this window]
[in a new window]
  		FIGURE 5. Mobilization of mouse bone marrow eosinophils by CCL16 via H4. A, Rapid mobilization of eosinophils by CCL16. Mice were injected i.v. with 100 µl of PBS ({circ}) or PBS containing 0.5 nmol of CCL16 (•). At indicated time points, differential cell counts were made for peripheral blood and bone marrow. Each point represents mean ± SEM from five separate experiments. B, Suppression of CCL16-induced eosinophil mobilization by thioperamide. Mice were injected i.v. with 100 µl of PBS ({square}), PBS containing 0.5 nmol of CCL16 ({blacksquare}), or PBS containing 0.5 nmol of CCL16 and 250 nmol of thioperamide (). After 60 min, differential cell counts were made for peripheral blood and bone marrow. Each point represents mean ± SEM from five separate experiments.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
Histamine is an important biogenic amine and one of the major products of mast cells. Histamine exerts diverse physiological functions via four subtypes of histamine receptors, namely, H1, H2, H3, and H4, which are all GPCRs (18). These receptors are differentially expressed in various types of cells and mediate diverse effects by coupling with different classes of G proteins (10, 11, 12, 18). For example, H1 triggers responses such as smooth muscle contraction and vascular permeability and plays an important role in allergy, while H2 mediates gastric acid secretion. H3 is expressed in the CNS and controls release of histamine and neurotransmitters by neurons (18). Notably, H1, H2, and H3 share less protein sequence identity with each other than with other biogenic amine receptor family members, suggesting that they may have evolved from different ancestral genes (Fig. 6). H4 is the most recently identified subtype of histamine receptor with an amino acid identity of ~38% to H3 (9, 10). H4 has been shown to be primarily expressed by eosinophils and responsible for histamine-induced migration of eosinophils (10, 11). In the present study, we have demonstrated that CCL16, which is a low-affinity ligand for CCR1, CCR2, CCR5, and CCR8 (6, 8), is also a novel agonist for H4. CCL16 induced vigorous calcium mobilization and chemotaxis through H4 (Figs. 1 and 2) and specifically bound to H4 with a Kd of 17 nM (Fig. 3). At the molar basis, CCL16 and histamine are almost equivalent in potency as an agonist for H4 (Figs. 2 and 3). Fig. 6 shows the phylogenic relationships of the chemokine receptors (for the sake of simplicity, only four members are shown) and the histamine receptors. Chemokine receptors are closely related to GPCRs for peptide ligands, while histamine receptors H1 and H2 are the members of GPCRs for biogenic amines. However, H3 and H4, which are most closely related to each other, are only remotely related to other biogenic amine receptors including H1 and H2 and have a closer phylogenic relationship with GPCRs for peptide ligands than other biogenic amine receptors. At any rate, this is the first time of a demonstration of an interaction of a chemokine with a GPCR quite different from the chemokine receptors. Given the versatility of the GPCR system, however, such unexpected interactions may be more frequent than anticipated.



View larger version (27K):
[in this window]
[in a new window]
  		FIGURE 6. Phylogenic relationships of histamine receptors with other GPCRs. A phylogenic tree was constructed from the amino acid sequences of indicated GPCRs. Evolutionary distances were generated using the program of Clustal W (http://clustalw.genome.ad.jp). Histamine receptors H1, H2, H3, and H4 are underlined.

 
In consistence with the selective expression of H4 in eosinophils (Fig. 4A) (10, 11), CCL16 induced vigorous migration in human and mouse eosinophils in vitro (Fig. 4) and rapid mobilization of bone marrow eosinophils into peripheral blood in mice (Fig. 5). Furthermore, thioperamide, an antagonist for H3 and H4 (10, 22), effectively suppressed all of those responses of eosinophils to CCL16 (Figs. 4 and 5). H3 is known to be selectively expressed in the CNS and primarily by neurons (18). By using RT-PCR, we confirmed that human and mouse eosinophils express H4 but not H3 (Fig. 4A). Furthermore, human eosinophils do not express CCR1, CCR2, CCR5, or CCR8 (23). Thus, it can be safely concluded that H4 mediates eosinophil responses to CCL16. Since CCL16 is constitutively expressed by the liver parenchymal cells and present in the normal plasma at relatively high concentrations (average, 50 ng/ml) (6), CCL16 may have a role in mobilization of eosinophils from the bone marrow (Fig. 5). In addition, CCL16 is known to be induced in monocytes by IL-10 (3). Therefore, CCL16 may be produced by monocytes and tissue macrophages in Th2-dominant inflammatory conditions and attract eosinophils into inflammatory sites. Furthermore, CCL16 and histamine, whose effects on H4 are additive (Fig. 2), may cooperatively promote eosinophil migration in allergic conditions. CCL16 may also play a significant role in certain liver diseases such as drug-induced liver damages that are known to be associated with liver infiltration of eosinophils and/or blood eosinophilia (24, 25, 26, 27). Furthermore, CCL16 may also play a role in migration of other hemopoietic cells such as dendritic cells and mast cells that also express H4 (12, 28). Even though CCL16 is effective only at relatively high concentrations, the versatility of CCL16 as a ligand for CCR1, CCR2, CCR5, CCR8, and even H4 may allow it to have a substantial role in trafficking of various types of hemopoietic cells. These possibilities remain to be seen.


   Acknowledgments
 
We thank Namie Sakiyama for excellent technical assistance.


   Footnotes
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported in part by a High-Tech Research Center Grant from the Ministry of Education, Culture, Sports, Science and Technology of Japan, by a grant from the Ministry of Health, Welfare, and Labor of Japan, and by Solution Oriented Research for Science and Technology of the Japan Science and Technology Corporation. Back

2 Address correspondence and reprint requests to Dr. Osamu Yoshie, Department of Microbiology, Kinki University School of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, Osaka 589-8511, Japan. E-mail address: o.yoshie{at}med.kindai.ac.jp Back

3 Abbreviations used in this paper: GPCR, G protein-coupled receptor; LEC, liver-expressed chemokine; PTX, pertussis toxin. Back

Received for publication January 13, 2004. Accepted for publication May 26, 2004.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Yoshie, O., T. Imai, H. Nomiyama. 2001. Chemokines in immunity. Adv. Immunol. 78:57.[Medline]
  2. Shoudai, K., K. Hieshima, S. Fukuda, M. Iio, R. Miura, T. Imai, O. Yoshie, H. Nomiyama. 1998. Isolation of cDNA encoding a novel human CC chemokine NCC-4/LEC. Biochim. Biophys. Acta 1396:273.[Medline]
  3. Hedrick, J. A., A. Helms, A. Vicari, A. Zlotnik. 1998. Characterization of a novel CC chemokine, HCC-4, whose expression is increased by interleukin-10. Blood 91:4242.[Abstract/Free Full Text]
  4. Youn, B. S., S. Zhang, H. E. Broxmeyer, K. Antol, M. J. Fraser, Jr, G. Hangoc, B. S. Kwon. 1998. Isolation and characterization of LMC, a novel lymphocyte and monocyte chemoattractant human CC chemokine, with myelosuppressive activity. Biochem. Biophys. Res. Commun. 247:217.[Medline]
  5. Yang, J. Y., K. S. Spanaus, U. Widmer. 2000. Cloning, characterization and genomic organization of LCC-1 (scya16), a novel human CC chemokine expressed in liver. Cytokine 12:101.[Medline]
  6. Nomiyama, H., K. Hieshima, T. Nakayama, T. Sakaguchi, R. Fujisawa, S. Tanase, H. Nishiura, K. Matsuno, H. Takamori, Y. Tabira, et al 2001. Human CC chemokine liver-expressed chemokine/CCL16 is a functional ligand for CCR1, CCR2 and CCR5, and constitutively expressed by hepatocytes. Int. Immunol. 13:1021.[Abstract/Free Full Text]
  7. Giovarelli, M., P. Cappello, G. Forni, T. Salcedo, P. A. Moore, D. W. LeFleur, B. Nardelli, E. D. Carlo, P. L. Lollini, S. Ruben, et al 2000. Tumor rejection and immune memory elicited by locally released LEC chemokine are associated with an impressive recruitment of APCs, lymphocytes, and granulocytes. J. Immunol. 164:3200.[Abstract/Free Full Text]
  8. Howard, O. M., H. F. Dong, A. K. Shirakawa, J. J. Oppenheim. 2000. LEC induces chemotaxis and adhesion by interacting with CCR1 and CCR8. Blood 96:840.[Abstract/Free Full Text]
  9. Oda, T., N. Morikawa, Y. Saito, Y. Masuho, S. Matsumoto. 2000. Molecular cloning and characterization of a novel type of histamine receptor preferentially expressed in leukocytes. J. Biol. Chem. 275:36781.[Abstract/Free Full Text]
  10. Liu, C., X. Ma, X. Jiang, S. J. Wilson, C. L. Hofstra, J. Blevitt, J. Pyati, X. Li, W. Chai, N. Carruthers, T. W. Lovenberg. 2001. Cloning and pharmacological characterization of a fourth histamine receptor (H4) expressed in bone marrow. Mol. Pharmacol. 59:420.[Abstract/Free Full Text]
  11. O’Reilly, M., R. Alpert, S. Jenkinson, R. P. Gladue, S. Foo, S. Trim, B. Peter, M. Trevethick, M. Fidock. 2002. Identification of a histamine H4 receptor on human eosinophils–role in eosinophil chemotaxis. J. Recept. Signal Transduct. Res. 22:431.[Medline]
  12. Hofstra, C. L., P. J. Desai, R. L. Thurmond, W. P. Fung-Leung. 2003. Histamine H4 receptor mediates chemotaxis and calcium mobilization of mast cells. J. Pharmacol. Exp. Ther. 305:1212.[Abstract/Free Full Text]
  13. Yang, D., O. Chertov, S. N. Bykovskaia, Q. Chen, M. J. Buffo, J. Shogan, M. Anderson, J. M. Schroder, J. M. Wang, O. M. Howard, J. J. Oppenheim. 1999. {beta}-Defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science 286:525.[Abstract/Free Full Text]
  14. Albini, A., S. Ferrini, R. Benelli, S. Sforzini, D. Giunciuglio, M. G. Aluigi, A. E. Proudfoot, S. Alouani, T. N. Wells, G. Mariani, et al 1998. HIV-1 Tat protein mimicry of chemokines. Proc. Natl. Acad. Sci. USA 95:13153.[Abstract/Free Full Text]
  15. Howard, O. M., H. F. Dong, D. Yang, N. Raben, K. Nagaraju, A. Rosen, L. Casciola-Rosen, M. Hartlein, M. Kron, K. Yiadom, et al 2002. Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells. J. Exp. Med. 196:781.[Abstract/Free Full Text]
  16. Fiore, S., J. F. Maddox, H. D. Perez, C. N. Serhan. 1994. Identification of a human cDNA encoding a functional high affinity lipoxin A4 receptor. J. Exp. Med. 180:253.[Abstract/Free Full Text]
  17. Su, S. B., W. Gong, J. L. Gao, W. Shen, P. M. Murphy, J. J. Oppenheim, J. M. Wang. 1999. A seven-transmembrane, G protein-coupled receptor, FPRL1, mediates the chemotactic activity of serum amyloid A for human phagocytic cells. J. Exp. Med. 189:395.[Abstract/Free Full Text]
  18. Hill, S. J., C. R. Ganellin, H. Timmerman, J. C. Schwartz, N. P. Shankley, J. M. Young, W. Schunack, R. Levi, H. L. Haas. 1997. International Union of Pharmacology. XIII. Classification of histamine receptors. Pharmacol. Rev. 49:253.[Abstract/Free Full Text]
  19. Yoshida, T., D. Izawa, T. Nakayama, K. Nakahara, M. Kakizaki, T. Imai, R. Suzuki, M. Miyasaka, O. Yoshie. 1999. Molecular cloning of mXCR1, the murine SCM-1/lymphotactin receptor. FEBS Lett. 458:37.[Medline]
  20. Nakayama, T., R. Fujisawa, D. Izawa, K. Hieshima, K. Takada, O. Yoshie. 2002. Human B cells immortalized with Epstein-Barr virus upregulate CCR6 and CCR10 and downregulate CXCR4 and CXCR5. J. Virol. 76:3072.[Abstract/Free Full Text]
  21. Tokui, M., I. Takei, F. Tashiro, A. Shimada, A. Kasuga, M. Ishii, T. Ishii, K. Takatsu, T. Saruta, J. Miyazaki. 1997. Intramuscular injection of expression plasmid DNA is an effective means of long-term systemic delivery of interleukin-5. Biochem. Biophys. Res. Commun. 233:527.[Medline]
  22. Liu, C., S. J. Wilson, C. Kuei, T. W. Lovenberg. 2001. Comparison of human, mouse, rat, and guinea pig histamine H4 receptors reveals substantial pharmacological species variation. J. Pharmacol. Exp. Ther. 299:121.[Abstract/Free Full Text]
  23. Nagase, H., M. Miyamasu, M. Yamaguchi, T. Fujisawa, K. Ohta, K. Yamamoto, Y. Morita, K. Hirai. 2000. Expression of CXCR4 in eosinophils: functional analyses and cytokine-mediated regulation. J. Immunol. 164:5935.[Abstract/Free Full Text]
  24. Terasaki, S., Y. Nakanuma, M. Yamazaki, M. Unoura. 1993. Eosinophilic infiltration of the liver in primary biliary cirrhosis: a morphological study. Hepatology 17:206.[Medline]
  25. Nagral, A., Z. Ben-Ari, A. P. Dhillon, A. K. Burroughs. 1998. Eosinophils in acute cellular rejection in liver allografts. Liver Transplant. Surg. 4:355.[Medline]
  26. Larrey, D.. 1995. Drug-induced hepatitis: epidemiologic, clinical, diagnostic and physiopathologic aspects in 1995. Rev. Med. Interne 16:752.[Medline]
  27. Dansette, P. M., E. Bonierbale, C. Minoletti, P. H. Beaune, D. Pessayre, D. Mansuy. 1998. Drug-induced immunotoxicity. Eur. J. Drug Metab. Pharmacokinet. 23:443.[Medline]
  28. Gantner, F., K. Sakai, M. W. Tusche, W. W. Cruikshank, D. M. Center, K. B. Bacon. 2002. Histamine H4 and H2 receptors control histamine-induced interleukin-16 release from human CD8+ T cells. J. Pharmacol. Exp. Ther. 303:300.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 J. Immunol.Home page
B. B. Damaj, C. B. Becerra, H. J. Esber, Y. Wen, and A. A. Maghazachi
Functional Expression of H4 Histamine Receptor in Human Natural Killer Cells, Monocytes, and Dendritic Cells
J. Immunol., December 1, 2007; 179(11): 7907 - 7915.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
L E Sander, A Lorentz, G Sellge, M Coeffier, M Neipp, T Veres, T Frieling, P N Meier, M P Manns, and S C Bischoff
Selective expression of histamine receptors H1R, H2R, and H4R, but not H3R, in the human intestinal tract
Gut, April 1, 2006; 55(4): 498 - 504.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
Y. Watanabe, T. Nakayama, D. Nagakubo, K. Hieshima, Z. Jin, F. Katou, K. Hashimoto, and O. Yoshie
Dopamine Selectively Induces Migration and Homing of Naive CD8+ T Cells via Dopamine Receptor D3
J. Immunol., January 15, 2006; 176(2): 848 - 856.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
R. Gutzmer, C. Diestel, S. Mommert, B. Kother, H. Stark, M. Wittmann, and T. Werfel
Histamine H4 Receptor Stimulation Suppresses IL-12p70 Production and Mediates Chemotaxis in Human Monocyte-Derived Dendritic Cells
J. Immunol., May 1, 2005; 174(9): 5224 - 5232.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nakayama, T.
Right arrow Articles by Yoshie, O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nakayama, T.
Right arrow Articles by Yoshie, O.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS